Zacks Research Issues Optimistic Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Zacks Research boosted their Q1 2026 EPS estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Monday, April 28th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, up from their previous estimate of ($0.20). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ FY2026 earnings at ($0.40) EPS and Q1 2027 earnings at $0.03 EPS.

ESPR has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. The Goldman Sachs Group cut their price objective on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Thursday, April 17th. Needham & Company LLC reiterated a “buy” rating and issued a $5.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.42.

Esperion Therapeutics Stock Up 4.1 %

ESPR opened at $1.00 on Wednesday. The business’s fifty day simple moving average is $1.34 and its 200 day simple moving average is $1.94. Esperion Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.94. The stock has a market cap of $198.03 million, a PE ratio of -1.56 and a beta of 0.86.

Institutional Investors Weigh In On Esperion Therapeutics

A number of large investors have recently made changes to their positions in ESPR. Wasatch Advisors LP lifted its stake in shares of Esperion Therapeutics by 4.9% in the 4th quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock valued at $53,861,000 after purchasing an additional 1,136,245 shares during the period. Nuveen Asset Management LLC lifted its stake in shares of Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the period. Bank of America Corp DE lifted its stake in shares of Esperion Therapeutics by 45.1% in the 4th quarter. Bank of America Corp DE now owns 1,629,980 shares of the biopharmaceutical company’s stock valued at $3,586,000 after purchasing an additional 506,428 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Esperion Therapeutics by 18.6% in the 4th quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 385,099 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Esperion Therapeutics by 31.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 220,730 shares during the period. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.